Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity.
about
Protein Phosphatase 2A as a Therapeutic Target in Acute Myeloid LeukemiaThe Basic Biology of PP2A in Hematologic Cells and MalignanciesPP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effectsOverexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2ANovel B55α-PP2A mutations in AML promote AKT T308 phosphorylation and sensitivity to AKT inhibitor-induced growth arrest.Phosphorylation of a constrained azacyclic FTY720 analog enhances anti-leukemic activity without inducing S1P receptor activation.Sphingosine kinase 1 is a potential therapeutic target for nasopharyngeal carcinoma.Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): an oncoprotein with many hands.Role of Sphingolipids and Metabolizing Enzymes in Hematological Malignancies.The antineoplastic properties of FTY720: evidence for the repurposing of fingolimod.Reprogramming the oncogenic response: SET protein as a potential therapeutic target in cancer.PROTOCADHERIN 7 Acts through SET and PP2A to Potentiate MAPK Signaling by EGFR and KRAS during Lung Tumorigenesis.Deregulation of the protein phosphatase 2A, PP2A in cancer: complexity and therapeutic options.MYC-dependent recruitment of RUNX1 and GATA2 on the SET oncogene promoter enhances PP2A inactivation in acute myeloid leukemia.CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia.Upregulation of the oncoprotein SET determines poor clinical outcomes in hepatocellular carcinoma and shows therapeutic potential.Identification of PP2A/Set Binding Sites and Design of Interacting Peptides with Potential Clinical Applications
P2860
Q26752430-0A7653D5-087E-40B5-A523-D996300BF519Q28088697-2BDE512F-B583-44A8-B618-CA4E4633CA69Q35552005-22ED31BB-3849-4F03-80D8-6EFF71A641E2Q36020877-A3374D57-DDA1-44E4-A742-E85DF7E577F4Q36729492-DEB62EBB-B5B9-4A8D-9E2C-E5D42E1A700FQ37641562-F1C6B7F4-14E1-45DD-80EF-5C0E32120CEAQ37675273-16707FE6-53C8-4ACC-A2E4-C7492912CA14Q37697046-0C9A76E0-99F2-424F-8E0B-77291E4BB5BEQ38228491-100BF18A-0420-4AF5-96A6-937B85352565Q38495744-429AADFB-23F4-41A1-93EC-E7BABB3A33EBQ38546700-BEB07319-823C-4674-A2F2-BA308151B3EDQ38678579-AA1A5E1C-B088-4A8D-ACDC-6DF50F4C9CA4Q38732488-0AD70377-00D7-48CC-BAB5-75D0523C9F80Q38904928-D69C2A2E-1164-4730-9772-E322E5FCC33AQ41553595-8C8E03E2-77AE-4510-B7C8-0676C1C6D72AQ42573854-5F0822B5-8CC6-4739-9951-467233968991Q48064023-2EDB56F4-733B-4CC8-9DDD-C1A0F36731FFQ58374470-1EC65B9E-937E-4D5F-8F95-FEB1E9482F94
P2860
Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Effect of FTY720 on the SET-PP ...... gs have antagonistic activity.
@en
Effect of FTY720 on the SET-PP ...... gs have antagonistic activity.
@nl
type
label
Effect of FTY720 on the SET-PP ...... gs have antagonistic activity.
@en
Effect of FTY720 on the SET-PP ...... gs have antagonistic activity.
@nl
prefLabel
Effect of FTY720 on the SET-PP ...... gs have antagonistic activity.
@en
Effect of FTY720 on the SET-PP ...... gs have antagonistic activity.
@nl
P2093
P2860
P356
P1433
P1476
Effect of FTY720 on the SET-PP ...... ugs have antagonistic activity
@en
P2093
A Dominguez
D J Christensen
I Moreno-Miralles
P2860
P2888
P304
P356
10.1038/LEU.2014.141
P577
2014-04-30T00:00:00Z